Burnett Patrick's Form 4 filing
Arcutis Biotherapeutics, Inc. (ARQT) · filed Mar 3, 2026
- Accession no.
- 0001628280-26-014324
- Filed
- Mar 3, 2026
- Trade date
- Aug 18, 2022-Mar 2, 2026
- Filing delay
- 1,293 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $158.3K. It was filed 1293 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Burnett PatrickCIK 0001741987 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2022 | Common Stock | AGrant or awardAcquired | +16,750 | $0.00 | $0 | 97,401 | Direct | |
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +30,000 | $0.00 | $0 | 127,401 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −6,106 | $25.16 | −$153,626.96 | 121,295 | Direct | |
| Mar 2, 2026 | Common Stock | SSaleDisposed | −181 | $25.91 | −$4,689.71 | 121,150 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 27, 2026 | Common Stock | AGrant or awardAcquired | +77,000 | $0.00 | $0 | 77,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.